Lipid Nanoparticles as Delivery Vehicles for Inhaled Therapeutics

Lipid nanoparticles (LNPs) have emerged as a powerful non-viral carrier for drug delivery. With the prevalence of respiratory diseases, particularly highlighted by the current COVID-19 pandemic, investigations into applying LNPs to deliver inhaled therapeutics directly to the lungs are underway. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Leong, Ellenmae W. X., Ge, Ruowen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496059/
https://www.ncbi.nlm.nih.gov/pubmed/36140280
http://dx.doi.org/10.3390/biomedicines10092179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496059/
https://www.ncbi.nlm.nih.gov/pubmed/36140280
http://dx.doi.org/10.3390/biomedicines10092179

Ejemplares similares